Michael Zhang, MD
Urology · Stockton, CANPI 1275920977
Payments from drug & device makers
Across 49 payments — averaging $110.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Cook Medical LLC$340
- Octapharma USA, Inc.$183
- Boston Scientific$126
- Johnson & Johnson$116
- Accord Healthcare, Inc.$74
- plus $559 from 19 others
What the payments were for
- Speaking & faculty fees$4,00074%
- Food & beverage$1,39826%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 2 | $4,000 |
| Cook Medical LLC | 8 | $340 |
| Octapharma USA, Inc. | 2 | $183 |
| Boston Scientific | 3 | $126 |
| Johnson & Johnson(2 entities) | 4 | $116 |
| Accord Healthcare, Inc. | 3 | $74 |
| Coloplast | 4 | $64 |
| Teleflex LLC | 3 | $54 |
| Axonics, Inc. | 3 | $52 |
| Procept Biorobotics Corporation | 2 | $44 |
| Convatec Inc. | 1 | $41 |
| MDD US Operations, LLC | 1 | $32 |
| Myriad Genetic Laboratories, Inc. | 1 | $29 |
| Tolmar, Inc. | 1 | $29 |
| Ambu Inc. | 1 | $25 |
| AstraZeneca | 1 | $24 |
| Dentsply IH AB | 1 | $23 |
| Merck | 1 | $22 |
| Pfizer | 1 | $22 |
| AbbVie | 1 | $21 |
| UCB, Inc. | 1 | $18 |
| Agiliti Surgical, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Laborie Medical Technologies Corp. | 1 | $15 |
| Viiv Healthcare Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,000
- PANZYGA$161
- Zenith Spiral-Z$127
How this compares
$5,398 in reported general payments places this provider in the 65th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 23 | $315,182 |
| MyrbetriqMirabegron | 333 | $188,563 |
| GemtesaVibegron | 21 | $27,529 |
| Mirabegron ErMirabegron | 32 | $13,420 |
| Tamsulosin Hcl | 466 | $7,861 |
| Finasteride | 480 | $7,188 |
| Trospium Chloride ErTrospium Chloride | 39 | $4,839 |
| Oxybutynin Chloride ErOxybutynin Chloride | 202 | $4,068 |
| Estradiol | 72 | $3,976 |
| Methenamine Hippurate | 39 | $2,693 |
| Solifenacin Succinate | 40 | $1,924 |
| Tolterodine Tartrate ErTolterodine Tartrate | 24 | $1,828 |
| Testosterone Cypionate | 35 | $921 |
| Potassium Citrate ErPotassium Citrate | 14 | $908 |
| Bicalutamide | 49 | $906 |
Paid to pharmacies, not to this prescriber.
Other urology in Stockton
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Ralph ClaymanOrange$3.9M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
- John KowalczykLos Angeles$1.8M
- Arie BelldegrunLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.